probenecid has been researched along with Benign Neoplasms in 14 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, characterization of the UGT1A locus and genetic studies directed at understanding the role of bilirubin glucuronidation and the biochemical basis of the clinical symptoms found in unconjugated hyperbilirubinemia have uncovered the structural gene polymorphisms associated with Crigler-Najjar's and Gilbert's syndrome." | 4.80 | Human UDP-glucuronosyltransferases: metabolism, expression, and disease. ( Strassburg, CP; Tukey, RH, 2000) |
| " The aim of this phase I study was to determine the maximum-tolerated dose of pralatrexate when combined with probenecid given every 2 weeks in humans." | 2.72 | A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors. ( Azzoli, CG; Fury, MG; Kemeny, N; Kris, MG; Krug, LM; Rizvi, NA; Sharma, S; Wu, N, 2006) |
| "Pretreatment with probenecid (PBC) led to a doubling of the serum MTX level and a significant increase in the area under the concentration-time curve." | 2.66 | Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid. ( Lilly, MB; Omura, GA, 1985) |
| "Probenecid did not increase the exposure of MTX inside the tumor, but caused a longer half-life of central MTX." | 1.36 | The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study. ( Böhlke, M; Henry, K; Kim, J; Maher, TJ; Sani, SN; Stricker-Krongrad, A, 2010) |
| "Seven additional cancer patients were treated with probenecid prior to CP." | 1.27 | Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. ( Coleman, CN; Hirst, K; Jacobs, C; Rich, L; Weiner, MW, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (35.71) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tukey, RH | 1 |
| Strassburg, CP | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Itahana, Y | 1 |
| Han, R | 1 |
| Barbier, S | 1 |
| Lei, Z | 1 |
| Rozen, S | 1 |
| Itahana, K | 1 |
| Ahmed, MU | 1 |
| Bennett, DJ | 1 |
| Hsieh, TC | 1 |
| Doonan, BB | 1 |
| Ahmed, S | 1 |
| Wu, JM | 1 |
| Sani, SN | 1 |
| Henry, K | 1 |
| Böhlke, M | 1 |
| Kim, J | 1 |
| Stricker-Krongrad, A | 1 |
| Maher, TJ | 1 |
| Campos-Arroyo, D | 1 |
| Martínez-Lazcano, JC | 1 |
| Melendez-Zajgla, J | 1 |
| Fury, MG | 1 |
| Krug, LM | 1 |
| Azzoli, CG | 1 |
| Sharma, S | 1 |
| Kemeny, N | 1 |
| Wu, N | 1 |
| Kris, MG | 1 |
| Rizvi, NA | 1 |
| Jacobs, C | 2 |
| Coleman, CN | 2 |
| Rich, L | 1 |
| Hirst, K | 1 |
| Weiner, MW | 1 |
| Lizard, G | 1 |
| Chignol, MC | 1 |
| Chardonnet, Y | 1 |
| Schmitt, D | 1 |
| Howell, SB | 1 |
| Olshen, RA | 1 |
| Rice, JA | 1 |
| Kaubisch, S | 1 |
| Halsey, J | 1 |
| Lum, BL | 1 |
| Gosland, M | 1 |
| Sikic, BI | 1 |
| Lilly, MB | 1 |
| Omura, GA | 1 |
| Tattersall, MH | 1 |
| Hutchinson, RM | 1 |
| Gaya, H | 1 |
| Spiers, AS | 1 |
| Bodey, GP | 1 |
| Rodriguez, V | 1 |
| Stewart, D | 1 |
3 reviews available for probenecid and Benign Neoplasms
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; | 2000 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Repositioning of drugs using open-access data portal DTome: A test case with probenecid (Review).
Topics: Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; Antiviral Agents; Databases, Pharmaceutical | 2016 |
3 trials available for probenecid and Benign Neoplasms
| Article | Year |
|---|---|
A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Area Un | 2006 |
The use of probenecid as a chemoprotector against cisplatin nephrotoxicity.
Topics: Adult; Aged; beta 2-Microglobulin; Cisplatin; Creatinine; Dose-Response Relationship, Drug; Drug Eva | 1991 |
Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid.
Topics: Administration, Oral; Clinical Trials as Topic; Drug Administration Schedule; Humans; Methotrexate; | 1985 |
8 other studies available for probenecid and Benign Neoplasms
| Article | Year |
|---|---|
The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense.
Topics: Antioxidants; Biological Transport; Cell Line, Tumor; DNA Damage; Glucose Transport Proteins, Facili | 2015 |
The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study.
Topics: Animals; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cyclosporine; Drug Delivery Systems; D | 2010 |
Probenecid is a chemosensitizer in cancer cell lines.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplati | 2012 |
Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid.
Topics: Cisplatin; Creatinine; Humans; Kidney; Metabolic Clearance Rate; Neoplasms; Probenecid | 1984 |
Active cell membrane mechanisms involved in the exclusion of Rh 123 allow distinction between normal and tumoral cells.
Topics: Cell Membrane; Cells, Cultured; Drug Resistance, Multiple; Fibroblasts; Flow Cytometry; Humans; Neop | 1994 |
Effect of probenecid on cerebrospinal fluid methotrexate kinetics.
Topics: Adult; Child, Preschool; Female; Humans; Kinetics; Methotrexate; Middle Aged; Neoplasms; Probenecid | 1979 |
Empirical antibiotic therapy in febrile patients with neutropenia and malignant disease.
Topics: Agranulocytosis; Anti-Bacterial Agents; Bacterial Infections; Carbenicillin; Cephalothin; Clindamyci | 1973 |
Clinical pharmacological studies of carbenicillin.
Topics: Adult; Aged; Humans; Injections, Intravenous; Kidney Function Tests; Leukemia; Lymph; Middle Aged; N | 1969 |